We lower adjusted EBIT by 13% for 2025E and 6% for 2026E-27E.
H1e likely in line with guidance ONH is the growth engine, Sonans growth turns positive Fair value r...
Q2e: Clean paper EBIT of ~PLN 10m Challenging markets Fair value range of SEK 25-70 Q2e Paper EBIT ...
Redeye leaves its preview of RaySearch’s Q2 2025 results due on Friday, August 8.
Redeye comments on last week's news where Google lost its antitrust appeal related to its app store ...
The combination of ELEVIDYS from Sarepta and Imlifidase records early supportive top-line data for p...
Delays weigh down the quarter’s results.
Redeye gives an initial comment on the Leqembi royalty for Q2 and the presentations from AAIC.
Cancom Q2 PW and cut FY'25 EBITA guidance by -25%, stock -8% Blames reluctant customers, and particu...
BeammWave has formalised its long-standing collaboration with Nitto Denko through a Joint Developmen...
Redeye comments on the partnership with SD Pharma in Spain, which will broaden physician reach of Pe...
Adtraction redovisade minskad nettoomsättning och EBITA i det andra kvartalet.
Redeye views the recently announced progress on US reimbursements positively, as a second payor has ...
The delayed launch is a setback for both XVIVO, patients and specialist centers waiting to use the s...
Mendus has fortified its intellectual property (IP) profile for lead candidate, vididencel, with the...
Market environment has remained slow Etteplan released a profit warning due to persistently weak ma...
Redeye provides a short comment on the recently announced directed issue from Scandinavian ChemoTech...
Redeye provides a comment on DalaVind’s divestment of Fageråsen, an onshore wind project of more tha...
Vaisala’s Q2 fell short of our estimates due to weaker than expected performance in W&E.
Some customers have postponed their orders due to uncertainties related to the US trade war.
